Pharmaceutical Outsourcing Present and Future

Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.

With the bio/pharmaceutical industry facing patent expirations in the near-term for key drugs, bio/pharma companies are facing the pressure of staying competitive in a bio/pharmaceutical landscape where the therapies are growing increasingly complex amid a major shift toward personalized medicines. Pharmaceutical Technology® spoke with Informa Markets about the critical role outsourcing plays in today’s competitive environment as well as into the future.

Read this article in Pharmaceutical Technology’s Bio/Pharma Outsourcing Innovation eBook.

About the author

Outsourcing Innovation eBook February 2024

Read the article: Pharmaceutical Outsourcing Present and Future

Read the eBook: Pharmaceutical Technology/Pharmaceutical Technology Europe Outsourcing Innovation eBook February 2024

Chris Spivey is the editorial director of Pharmaceutical Technology® and Pharmaceutical Technology Europe®.

Article details

Pharmaceutical Technology/Pharmaceutical Technology Europe Outsourcing Innovation eBook
Issue 2
February 2024
Pages: 31-32

Citation

When referring to this article, please cite it as Spivey, C. Pharmaceutical Outsourcing Present and Future. Pharmaceutical Technology, Bio/Pharma Outsourcing Innovation eBook. February 2024.

Articles in this issue

over 2 years ago

Article

Managing the Complexity of Modern Sterile Product Developments

over 2 years ago

Article

Navigating the Preclinical CRO Outsourcing Process

over 2 years ago

Article

A Closer Look at Affinity Ligands

over 2 years ago

Article

Ensuring Quality in Contracted Support

over 2 years ago

Article

How to Evaluate a CDMO’s Commitment to Quality

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Related to this article

October 22nd, 2026

Rare Pediatric PRVs: Manufacturing Strategies for Expedited Approval, Part 2: CMC and Regulations

Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.

October 22nd, 2026

Ask the Expert: Choosing Ingredient Suppliers

Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.

OpenAI acquires Orchestra Bio, adding AI agents for drug program coordination to its Rosalind suite.

October 20th, 2026

OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio

OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.